Mammary Cell News Volume 3.09 | Mar 10 2011

 Cell Therapy News is now on Facebook. Join us!

 Follow us on Twitter! @MammaryCell

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at info@connexoncreative.com

The Lancet Publishes Results from Pivotal Study of Eisai’s Halaven™ (Eribulin Mesylate) Injection in Patients with Late-Stage Metastatic Breast Cancer
Eisai announced that results from the global Phase III clinical study “EMBRACE” (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus Eribulin) was published. [Press release from Eisai Co., Ltd. discussing online prepublication in The Lancet]

Breast Cancer Survivors at Higher Risk for Falls; Cancer Therapies May Affect Balance, According to New Study
Researchers found evidence that women who have survived breast cancer may fall more often than their peers. [Press release from Oregon Health & Science University discussing online prepublication in the Archives of Physical Medicine and Rehabilitation]

Novel Clinical Trial Aims to Reduce Recurrence of Aggressive Breast Cancer
In a first-of-its-kind clinical trial, physician-scientists at University Hospitals Case Medical Center are exploring a new method to potentially prevent recurrence of an early stage, aggressive type of breast cancer. [University Hospitals Press Release]

LABORATORY RESEARCH

Annexin-1 Interacts with NEMO and RIP1 to Constitutively Activate I?B Kinase Complex and Nuclear Factor-?B: Implication in Breast Cancer Metastasis
The molecular mechanisms underlying constitutive nuclear factor-?B activation in solid tumors has not been elucidated. Scientists show that Annexin-1 (ANXA1) is involved in this process, and suppression of ANXA1 in highly metastatic breast cancer cells impedes migration and metastasis capabilities in vitro and in vivo. [Oncogene]

Identification of PUMA as an Estrogen Target Gene That Mediates the Apoptotic Response to Tamoxifen in Human Breast Cancer Cells and Predicts Patient Outcome and Tamoxifen Responsiveness in Breast Cancer
Here, researchers have identified the BCL-2 homology 3-only, pro-apoptotic regulator, PUMA (p53 upregulated modulator of apoptosis) as an estrogen target gene that is acutely downregulated in response to estrogen in breast cancer cell lines, independently of their p53 status. [Oncogene]

Alternative TFAP2A Isoforms Have Distinct Activities in Breast Cancer
Findings suggest that TFAP2A isoforms may be differentially regulated during breast tumorigenesis and this, coupled with differences in their transcriptional activity, may impact on tumor responses to tamoxifen therapy. [Breast Cancer Res]

Anti-Tumor Activity of the Hsp90 Inhibitor IPI-504 in HER2 Positive Trastuzumab-Resistant Breast Cancer
The aim of this study was to assess the anti-tumor activity of the heat shock protein 90 (Hsp90) inhibitor IPI-504 in trastuzumab-resistant, HER2 overexpressing breast cancer cells. [Mol Cancer Ther]

Primary Tumor Dependent Inhibition of Tumor Growth, Angio-Genesis, and Perfusion of Secondary Breast Cancer in Bone
Since breast cancer has a high propensity to spread to bone, scientists used an in vivo xenograft model to determine the impact of growing breast cancer cells (MCF-7) in the mammary fat pad on the microvascular properties of subsequently inoculated secondary breast cancer tumors in bone. [J Orthop Res]

Pre- and Postpubertal Irradiation Induces Mammary Cancers with Distinct Expression of Hormone Receptors, Erbb Ligands, and Developmental Genes in Rats
Here researchers examined how the mechanism of cancer development relates to the age at exposure to ionizing radiation or the carcinogen 1-methyl-1-nitrosourea. [Mol Carcinog]

DNA Methylation Changes in Murine Breast Adenocarcinomas Allow the Identification of Candidate Genes for Human Breast Carcinogenesis
Investigators present a model in which comparative epigenetic techniques can be used to identify novel candidate genes important for human breast tumorigenesis, in both primary and metastatic tumors. [Mamm Genome]

CLINICAL RESEARCH

Eribulin Monotherapy Versus Treatment of Physician’s Choice in Patients with Metastatic Breast Cancer (EMBRACE): A Phase III Open-Label Randomized Study
Scientists aimed to compare overall survival of heavily pretreated patients receiving eribulin versus currently available treatments. [Lancet]

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
This Phase III study compared the efficacy and safety of bevacizumab when combined with several standard chemotherapy regimens versus those regimens alone for first-line treatment of patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. [J Clin Oncol]

Serum HER2 Testing in Patients with HER2-Positive Breast Cancer: The Death Knell Tolls
Researchers assessed whether identification of circulating concentrations of human epidermal growth factor receptor 2 (HER2) extracellular domain have clinical usefulness for management of patients with HER2-positive breast cancer. [Lancet Oncology]

Methylated Genes in Breast Cancer: Associations with Clinical and Histopathological Features in a Familial Breast Cancer Cohort
Investigators compared associations of DNA methylation with tumor stage, hormone/growth receptor status, and clinical outcomes in a familial breast cancer cohort. [Cancer Biol Ther]

Identifying Factors Associated with Falls in Postmenopausal Breast Cancer Survivors: A Multi-Disciplinary Approach
The objective of the study is to identify neuromuscular, balance, and vision factors that contribute to falls in recently treated breast cancer survivors and explore links between fall risk factors and cancer treatment. [Arch Phys Med Rehabil]

Australia Fellowship Gives $4 Million Boost to Cancer Origin Research
Walter and Eliza Hall Institute cancer researcher Professor Jane Visvader has received a $4 million fellowship from the Australian Government to continue her work into the origin of breast, ovarian and lung cancers. [Walter and Eliza Hall Institute Press Release]

Avon Awards Breast Cancer Funds in Forsyth
The Forsyth Medical Center Foundation has received a $37,000 grant from The Avon Breast Health Outreach Program that will be used to provide awareness programs to medically underserved women. [The Business Journal]

TELUS and the Jewish General Hospital Foundation Join Together to Fight Breast Cancer
The Jewish General Hospital (JGH) Foundation is delighted to announce a $100,000 contribution from TELUS to help purchase digital mammography units for the Marlene & Joel King Breast Centre at the Segal Cancer Centre in the JGH of Montreal. [TELUS Press Release]

Caterpillar Pledges $2 Million to Fight Breast Cancer
The Caterpillar Foundation plans to donate $2 million to boost awareness of breast cancer in Latin America and improve treatment of the disease. [Chicago Tribune]

Massachusetts General Hospital Is First in the Nation to Do Mammography Screening Using 3D Breast Tomosynthesis
The Breast Imaging Program at Massachusetts General Hospital welcomed its first patient to undergo three-dimensional breast tomosynthesis screening. [Massachusetts General Hospital Press Release]

Nottingham Named as Site of New Breast Cancer Tissue Bank
Nottingham has been named as one of the key locations of the world’s first national breast cancer tissue bank. [Nottingham University Hospitals Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Post-doctoral Position (University of Pittsburgh)

Post-doctoral Position (National Cancer Centre Singapore)

Post-doctoral Position (Wayne State University School of Medicine)

Post-doctoral Research Associate (University of Wisconsin-Madison)

Post-doctoral Position Metastasis Research Laboratory (University of Liege) 

Post-doctoral Fellow (University of Texas Medical School at Houston) 

PhD Program – Tumor Cell Intrinsic Signaling Pathways that Regulate Immune Suppression (Lady Davis Institute of Medical Research)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.